Evolent Health, Inc. cash flow to debt ratio of 3.92% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Evolent Health, Inc.'s free cash flow has increased -177.59% from $-6.13M last year to $4.75M, signaling increasing performance

Evolent Health, Inc.'s debt to equity ratio is 2.53, which means that the company's assets are unhealthy financed, signaling financial risk.

Evolent Health, Inc.'s debt has increased relative to shareholder equity from 0.71 last year to 2.53 today, signaling weakened financials

Evolent Health, Inc. has negative EBITDA, making leverage ratio unreliable

Evolent Health, Inc.'s interest coverage ratio is -0.41, which means that the company struggles to meet interest obligations, signaling financial risk.

Evolent Health, Inc.'s profit margin has decreased (898.36%) in the last year from -2.41% to -24.08%, signaling decreasing performance

Evolent Health, Inc.'s short-term assets of $506.37M exceed its short-term liabilities of $385.26M

Evolent Health, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Evolent Health, Inc.'s return on equity of -99.16%, is lower than 15.00%, indicating bad performance

Evolent Health, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Evolent Health, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Evolent Health, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Evolent Health, Inc. has a free cash flow yield of 1.08%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Evolent Health, Inc.'s yearly earnings has decreased 767.39% since last year from $-61.62M to $-534.51M, signaling decreasing performance

Evolent Health, Inc.'s yearly revenue has decreased 26.56% since last year from $2.55B to $1.88B, signaling decreasing performance

ROIC -1.94% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Evolent Health, Inc.'s 3-year revenue CAGR of 11.54% is positive, indicating growing revenue over the past 3 years

Evolent Health, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Evolent Health, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Evolent Health, Inc. has insufficient data to evaluate this check.

Evolent Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Evolent Health, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Evolent Health, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Evolent Health, Inc. is overvalued relative to its fair value price of -5.04 based on Earnings Fair Value model

Evolent Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Evolent Health, Inc. has a price-to-book ratio of 1.15x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Evolent Health, Inc. has a price-to-sales ratio of 0.21x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue